Altimmune (ALT) Other Non-Current Liabilities (2010 - 2026)

Altimmune (ALT) has 17 years of Other Non-Current Liabilities data on file, last reported at $5.8 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 36243.75% year-over-year to $5.8 million in Q1 2026; TTM through Mar 2026 was $5.8 million, a 36243.75% increase from a year earlier, with the FY2025 full-year figure at $5.8 million, up 7.94% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $5.8 million, up from $5.8 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for ALT reached as high as $5.8 million in Q1 2026 and fell as low as $16000.0 in Q1 2025.
• Historically, Other Non-Current Liabilities has averaged $2.7 million across 5 years, with a median of $2.2 million in 2022.
• Across the five-year window, Other Non-Current Liabilities plunged 99.01% in 2022 and soared 36243.75% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $60000.0 in 2022, then plunged by 33.33% to $40000.0 in 2023, then soared by 13225.0% to $5.3 million in 2024, then climbed by 7.94% to $5.8 million in 2025, then rose by 1.08% to $5.8 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $5.8 million in Q1 2026, $5.8 million in Q4 2025, and $5.8 million in Q3 2025.